Bradley Knight, Fhrs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3414911/publications.pdf

Version: 2024-02-01

307 papers

15,039 citations

18482 62 h-index 20961 115 g-index

325 all docs

325 docs citations

times ranked

325

8292 citing authors

#	Article	IF	CITATIONS
1	Pulmonary Vein Isolation for Paroxysmal and Persistent Atrial Fibrillation. Circulation, 2002, 105, 1077-1081.	1.6	1,047
2	Update on Cardiovascular Implantable Electronic Device Infections and Their Management. Circulation, 2010, 121, 458-477.	1.6	919
3	Safety and Efficacy of a Totally Subcutaneous Implantable-Cardioverter Defibrillator. Circulation, 2013, 128, 944-953.	1.6	486
4	Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator. Journal of the American College of Cardiology, 2015, 65, 1605-1615.	2.8	458
5	Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. Journal of the American College of Cardiology, 2002, 40, 100-104.	2.8	348
6	Facilitating Transthoracic Cardioversion of Atrial Fibrillation with Ibutilide Pretreatment. New England Journal of Medicine, 1999, 340, 1849-1854.	27.0	332
7	Diagnostic value of tachycardia features and pacing maneuvers during paroxysmal supraventricular tachycardia. Journal of the American College of Cardiology, 2000, 36, 574-582.	2.8	327
8	Effect of an irregular ventricular rhythm on cardiac output. American Journal of Cardiology, 1996, 78, 1433-1436.	1.6	313
9	A technique for the rapid diagnosis of atrial tachycardia in the electrophysiology laboratory. Journal of the American College of Cardiology, 1999, 33, 775-781.	2.8	256
10	Segmental Ostial Ablation to Isolate the Pulmonary Veins During Atrial Fibrillation. Circulation, 2002, 106, 1256-1262.	1.6	249
11	Differentiation of atypical atrioventricular node re-entrant tachycardia from orthodromic reciprocating tachycardia using a septal accessory pathway by the response to ventricular pacing. Journal of the American College of Cardiology, 2001, 38, 1163-1167.	2.8	245
12	EHRA/HRS/APHRS Expert Consensus on Ventricular Arrhythmias. Heart Rhythm, 2014, 11, e166-e196.	0.7	230
13	Anatomy of the Pulmonary Veins in Patients with Atrial Fibrillation and Effects of Segmental Ostial Ablation Analyzed by Computed Tomography. Journal of Cardiovascular Electrophysiology, 2003, 14, 150-155.	1.7	213
14	Effect of Verapamil and Procainamide on Atrial Fibrillation–Induced Electrical Remodeling in Humans. Circulation, 1997, 96, 1542-1550.	1.6	213
15	Early Safety and Efficacy of Percutaneous Left Atrial Appendage Suture Ligation. Journal of the American College of Cardiology, 2014, 64, 565-572.	2.8	200
16	Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. Journal of the American College of Cardiology, 1999, 33, 1964-1970.	2.8	198
17	Mechanistic Significance of Intermittent Pulmonary Vein Tachycardia in Patients with Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2002, 13, 645-650.	1.7	196
18	Clinical Consequences of Electrocardiographic Artifact Mimicking Ventricular Tachycardia. New England Journal of Medicine, 1999, 341, 1270-1274.	27.0	195

#	Article	IF	Citations
19	EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Europace, 2014, 16, 1257-1283.	1.7	194
20	Headâ€Toâ€Head Comparison of Arrhythmia Discrimination Performance of Subcutaneous and Transvenous ICD Arrhythmia Detection Algorithms: The START Study. Journal of Cardiovascular Electrophysiology, 2012, 23, 359-366.	1.7	192
21	Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: Report from a multicenter registry. Heart Rhythm, 2009, 6, 189-195.	0.7	164
22	Fully implantable and bioresorbable cardiac pacemakers without leads or batteries. Nature Biotechnology, 2021, 39, 1228-1238.	17.5	163
23	electrocardiography41This document was approved by the American College of Cardiology Board of Trustees in November 2001 and the American Heart Association Science Advisory and Coordinating Committee in August 2001.42When citing this document, the American College of Cardiology and the American Heart Association would appreciate the following citation format: Kadish AH. Buxton AE.	2.8	158
24	Kennedy HL, Knight BP, Mason JW, Schuger CD, Tracy C. Journal of the American College of Cardiology, Risk Stratification for Arrhythmic Sudden Cardiac Death. Circulation, 2011, 123, 2423-2430.	1.6	155
25	On-treatment comparison between corrective His bundle pacing and biventricular pacing for cardiac resynchronization: A secondary analysis of the His-SYNC Pilot Trial. Heart Rhythm, 2019, 16, 1797-1807.	0.7	155
26	Double potentials along the ablation line as a guide to radiofrequency ablation of typical atrial flutter. Journal of the American College of Cardiology, 2001, 38, 750-755.	2.8	147
27	Radiofrequency catheter ablation of inappropriate sinus tachycardia guided by activation mapping. Journal of the American College of Cardiology, 2000, 35, 451-457.	2.8	138
28	Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. Heart Rhythm, 2017, 14, 1456-1463.	0.7	137
29	Effect of Ventricular Shock Strength on Cardiac Hemodynamics. Journal of Cardiovascular Electrophysiology, 1998, 9, 791-797.	1.7	136
30	Long-term retention of cardiac resynchronization therapy. Journal of the American College of Cardiology, 2004, 44, 72-77.	2.8	134
31	Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation, 2021, 143, 7-17.	1.6	132
32	A Prospective Evaluation of Catheter Ablation of Ventricular Tachycardia as Adjuvant Therapy in Patients With Coronary Artery Disease and an Implantable Cardioverter-Defibrillator. Circulation, 1997, 96, 1525-1531.	1.6	129
33	The Use of Intracardiac Echocardiography and Other Intracardiac Imaging Tools to Guide Noncoronary Cardiac Interventions. Journal of the American College of Cardiology, 2009, 53, 2117-2128.	2.8	128
34	AHA/ACCF Scientific Statement on the Evaluation of Syncope. Journal of the American College of Cardiology, 2006, 47, 473-484.	2.8	125
35	A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation. Journal of the American College of Cardiology, 2000, 35, 1915-1918.	2.8	123
36	Inhaled nitric oxide in primary pulmonary hypertension. Journal of the American College of Cardiology, 1998, 32, 1068-1073.	2.8	119

#	Article	IF	CITATIONS
37	Long-Term Follow-Up After Radiofrequency Modification of the Atrioventricular Node in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 1997, 29, 113-121.	2.8	118
38	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE). Europace, 2017, 19, 465-511.	1.7	118
39	Mapping and ablation of ventricular tachycardia guided by virtual electrograms using a noncontact, computerized mapping system. Journal of the American College of Cardiology, 2000, 35, 414-421.	2.8	116
40	Short-Term Effect of Atrial Fibrillation on Atrial Contractile Function in Humans. Circulation, 1999, 99, 3024-3027.	1.6	111
41	Comparison of a novel rectilinear biphasic waveform with a damped sine wave monophasic waveform for transthoracic ventricular defibrillation. Journal of the American College of Cardiology, 1999, 34, 1595-1601.	2.8	109
42	A New Algorithm to Reduce Inappropriate Therapy in the Sâ€ICD System. Journal of Cardiovascular Electrophysiology, 2015, 26, 417-423.	1.7	107
43	Comparison of Effective and Ineffective Target Sites That Demonstrate Concealed Entrainment in Patients With Coronary Artery Disease Undergoing Radiofrequency Ablation of Ventricular Tachycardia. Circulation, 1997, 95, 183-190.	1.6	107
44	Real-Time Three-Dimensional Transesophageal Echocardiography of the Left Atrial Appendage: Initial Experience in the Clinical Setting. Journal of the American Society of Echocardiography, 2008, 21, 1362-1368.	2.8	106
45	Predictors of Device-Related Thrombus Following Percutaneous Left Atrial AppendageÂOcclusion. Journal of the American College of Cardiology, 2021, 78, 297-313.	2.8	106
46	Prevalence of central venous occlusion in patients with chronic defibrillator leads. American Heart Journal, 2001, 141, 813-816.	2.7	101
47	Role of Permanent Pacing to Prevent Atrial Fibrillation. Circulation, 2005, 111, 240-243.	1.6	100
48	Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm, 2014, 11, 1361-1366.	0.7	99
49	Complete atrioventricular block after valvular heart surgery and the timing of pacemaker implantation. American Journal of Cardiology, 2001, 87, 649-651.	1.6	93
50	Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm, 2016, 13, 1066-1074.	0.7	92
51	American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and	1.6	90
52	A transient, closed-loop network of wireless, body-integrated devices for autonomous electrotherapy. Science, 2022, 376, 1006-1012.	12.6	90
53	A Prospective Comparison of Cardiac Imaging Using Intracardiac Echocardiography With Transesophageal Echocardiography in Patients With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2010, 3, 571-577.	4.8	86
54	Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm, 2014, 11, 1352-1358.	0.7	86

#	Article	IF	CITATIONS
55	Role of the Coronary Sinus in Maintenance of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2003, 14, 1329-1336.	1.7	84
56	2:1 Atrioventricular Block During Atrioventricular Node Reentrant Tachycardia. Journal of the American College of Cardiology, 1996, 28, 1770-1774.	2.8	78
57	Physician interpretation of electrocardiographic artifact that mimics ventricular tachycardia. American Journal of Medicine, 2001, 110, 335-338.	1.5	76
58	Response to Pacing at Sites of Isolated Diastolic Potentials During Ventricular Tachycardia in Patients With Previous Myocardial Infarction. Journal of the American College of Cardiology, 1997, 30, 505-513.	2.8	72
59	Long-Term Outcomes After Ablation for Paroxysmal Atrial Fibrillation Using the Second-Generation Cryoballoon. JACC: Clinical Electrophysiology, 2019, 5, 306-314.	3.2	72
60	Cardiac Sarcoidosis Masquerading as Right Ventricular Dysplasia. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 1498-1503.	1.2	71
61	Cryoballoon versus Radiofrequency Catheter Ablation for Paroxysmal Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 483-489.	1.2	65
62	Verapamil decreases ventricular tachyarrhythmias in a patient with Timothy syndrome (LQT8). Heart Rhythm, 2006, 3, 967-970.	0.7	64
63	Effect of Coupling Interval and Pacing Cycle Length on Morphology of Paced Ventricular Complexes. Circulation, 1996, 94, 2843-2849.	1.6	64
64	Left Atrial Flutter After Segmental Ostial Radiofrequency Catheter Ablation for Pulmonary Vein Isolation. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 1417-1419.	1.2	63
65	Role of Transisthmus Conduction Intervals in Predicting Bidirectional Block after Ablation of Typical Atrial Flutter. Journal of Cardiovascular Electrophysiology, 2001, 12, 169-174.	1.7	62
66	Effects of Digoxin on Acute, Atrial Fibrillation–Induced Changes in Atrial Refractoriness. Circulation, 2000, 102, 2503-2508.	1.6	61
67	Electrogram morphology recurrence patterns during atrial fibrillation. Heart Rhythm, 2014, 11, 2027-2034.	0.7	59
68	Probability of Successful Defibrillation at Multiples of the Defibrillation Energy Requirement in Patients With an Implantable Defibrillator. Circulation, 1997, 96, 1217-1223.	1.6	59
69	Postmortem Interrogation and Retrieval of Implantable Pacemakers and Defibrillators: A Survey of Morticians and Patients. Journal of Cardiovascular Electrophysiology, 2007, 18, 478-482.	1.7	58
70	Implications and Outcome of Permanent Coronary Sinus Lead Extraction and Reimplantation. Journal of Cardiovascular Electrophysiology, 2005, 16, 830-837.	1.7	57
71	Successful Catheter Ablation of Hemodynamically Unstable Monomorphic Ventricular Tachycardia in a Patient with Hypertrophic Cardiomyopathy and Apical Aneurysm. Journal of Cardiovascular Electrophysiology, 2009, 20, 445-447.	1.7	57
72	Slow Pathway Ablation in Patients With Documented but Noninducible Paroxysmal Supraventricular Tachycardia. Journal of the American College of Cardiology, 1996, 28, 1000-1004.	2.8	56

#	Article	IF	Citations
73	Electrogram Polarity and Cavotricuspid Isthmus Block During Ablation of Typical Atrial Flutter. Journal of Cardiovascular Electrophysiology, 2001, 12, 393-399.	1.7	56
74	Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable. Circulation, 2019, 139, 1497-1506.	1.6	55
75	Effect of Chronic Amiodarone Therapy on Defibrillation Energy Requirements in Humans. Journal of Cardiovascular Electrophysiology, 2000, 11, 736-740.	1.7	52
76	Effect of Gender on Atrial Electrophysiologic Changes Induced by Rapid Atrial Pacing and Elevation of Atrial Pressure. Journal of Cardiovascular Electrophysiology, 2001, 12, 986-989.	1.7	50
77	Accuracy of the Unipolar Electrogram for Identification of the Site of Origin of Ventricular Activation. Journal of Cardiovascular Electrophysiology, 1997, 8, 974-979.	1.7	47
78	Novel coronavirus 19 (COVID-19) associated sinus node dysfunction: a case series. European Heart Journal - Case Reports, 2020, 4, 1-6.	0.6	47
79	Electrocardiographic differentiation of atrial flutter from atrial fibrillation by physicians. Journal of Electrocardiology, 1999, 32, 315-319.	0.9	46
80	Differentiation of Atrial and Pulmonary Vein Potentials Recorded Circumferentially Within Pulmonary Veins. Journal of Cardiovascular Electrophysiology, 2002, 13, 118-123.	1.7	45
81	Defibrillation Energy Requirements in an ICD Population Receiving Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2006, 17, 247-250.	1.7	45
82	Constitutive Expression of a Dominant-Negative TGF-β Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate. Circulation Research, 2016, 119, 69-82.	4.5	44
83	Effect of the Implantable Atrial Defibrillator on the Natural History of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 1999, 10, 1200-1209.	1.7	43
84	Acute changes in spontaneous echo contrast and atrial function after cardioversion of persistent atrial flutter. American Journal of Cardiology, 1998, 82, 1052-1055.	1.6	42
85	Effects of Simultaneous Atrioventricular Pacing on Atrial Refractoriness and Atrial Fibrillation Inducibility: Role of Atrial Mechanoelectrical Feedback. Journal of Cardiovascular Electrophysiology, 2001, 12, 43-50.	1.7	42
86	Response of Pulmonary Vein Potentials to Premature Stimulation. Journal of Cardiovascular Electrophysiology, 2002, 13, 33-37.	1.7	42
87	Procedural Patterns and Safety of Atrial Fibrillation Ablation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007944.	4.8	42
88	Contribution of Fibrosis and the Autonomic Nervous System to Atrial Fibrillation Electrograms in Heart Failure. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 640-649.	4.8	40
89	Direct visualization of coronary sinus ostium and branches with a flexible steerable fiberoptic infrared endoscope. Heart Rhythm, 2005, 2, 844-848.	0.7	39
90	Long-Term Evaluation of the Ventricular Defibrillation Energy Requirement. Journal of Cardiovascular Electrophysiology, 1998, 9, 916-920.	1.7	37

#	Article	IF	Citations
91	Prevalence of a Shared Isthmus in Postinfarction Patients with Pleiomorphic, Hemodynamically Tolerated Ventricular Tachycardias. Journal of Cardiovascular Electrophysiology, 2002, 13, 237-241.	1.7	36
92	Prevalence and Predictors of Cable Extrusion and Loss of Electrical Integrity with the Riata Defibrillator Lead. Journal of Cardiovascular Electrophysiology, 2012, 23, 1207-1212.	1.7	36
93	Effects of Electrocautery on Transvenous Lead Insulation Materials. Journal of Cardiovascular Electrophysiology, 2009, 20, 429-435.	1.7	35
94	Late Neurologic Events After Surgery for Atrial Fibrillation: Rare but Relevant. Annals of Thoracic Surgery, 2013, 95, 126-132.	1.3	35
95	The Safety of Cardiac and Thoracic Magnetic Resonance Imaging in Patients with Cardiac Implantable Electronic Devices. Academic Radiology, 2016, 23, 1498-1505.	2.5	35
96	Pulmonary Vein Isolation: Comparison of Bipolar and Unipolar Electrograms at Successful and Unsuccessful Ostial Ablation Sites. Journal of Cardiovascular Electrophysiology, 2002, 13, 13-19.	1.7	34
97	Factors Associated With High-Voltage Impedance and Subcutaneous Implantable Defibrillator Ventricular Fibrillation Conversion Success. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e006665.	4.8	33
98	Electrocardiographic predictors of successful ablation of tachycardia or bigeminy arising in the right ventricular outflow tract. American Journal of Cardiology, 1999, 84, 1266-1268.	1.6	32
99	Defibrillation energy requirements using a left anterior chest cutaneous to subcutaneous shocking vector: Implications for a total subcutaneous implantable defibrillator. Heart Rhythm, 2005, 2, 1332-1338.	0.7	32
100	Effects of operator experience on the outcome and duration of pulmonary vein isolation procedures for atrial fibrillation. American Journal of Cardiology, 2003, 91, 673-677.	1.6	31
101	Atrial Electrogram Amplitude and Efficacy of Cavotricuspid Isthmus Ablation for Atrial Flutter. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 1859-1863.	1.2	31
102	Bronchial effects of cryoballoon ablation for atrial fibrillation. Heart Rhythm, 2017, 14, 12-16.	0.7	31
103	Use of adenosine in patients hospitalized in a university medical center. American Journal of Medicine, 1998, 105, 275-280.	1.5	30
104	Predictors of Appropriate Defibrillator Therapy Among Patients with an Implantable Defibrillator That Delivers Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2006, 17, 486-490.	1.7	30
105	Therapy From a Novel Substernal Lead. JACC: Clinical Electrophysiology, 2019, 5, 186-196.	3.2	30
106	Cost Comparison of Radiofrequency Modification and Ablation of the Atrioventricular Junction in Patients With Chronic Atrial Fibrillation. Circulation, 1997, 96, 1532-1536.	1.6	30
107	A Prospective Evaluation of Two Defibrillation Safety Margin Techniques in Patients with Low Defibrillation Energy Requirements. Journal of Cardiovascular Electrophysiology, 1998, 9, 41-46.	1.7	29
108	Prescribing Exercise Training for Patients with Defibrillators. American Journal of Physical Medicine and Rehabilitation, 2000, 79, 292-297.	1.4	29

#	Article	IF	Citations
109	Left Atrial Thrombus After Appendage Closure Using LARIAT. Circulation: Arrhythmia and Electrophysiology, 2013, 6, e52-3.	4.8	28
110	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE). European Heart Journal, 2018, 39, ehw455.	2.2	28
111	Conduction recovery following pacemaker implantation after transcatheter aortic valve replacement. PACE - Pacing and Clinical Electrophysiology, 2018, 42, 146-152.	1.2	28
112	Gender and age differences in induced atrial fibrillation. American Journal of Cardiology, 2001, 88, 436-438.	1.6	27
113	Slow Pathway Ablation for Atrioventricular Nodal Reentry Using a Right Internal Jugular Vein Approach: A Case Series. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 59-62.	1.2	27
114	Long-Term Follow-Up After Radiofrequency Ablation of Paroxysmal Supraventricular Tachycardia in Patients With Tachycardia-Induced Atrial Fibrillation. American Journal of Cardiology, 1997, 80, 1609-1610.	1.6	26
115	Incidence of Tissue Coring During Transseptal Catheterization When Using Electrocautery and a Standard Transseptal Needle. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 341-344.	4.8	25
116	Changes in Cardiac Repolarization Following Short Periods of Ventricular Pacing. Journal of Cardiovascular Electrophysiology, 1998, 9, 269-280.	1.7	24
117	Randomized Comparison of Anatomic and Electrogram Mapping Approaches to Ablation of Typical Atrial Flutter. Journal of Cardiovascular Electrophysiology, 2002, 13, 662-666.	1.7	24
118	Randomized Comparison of Bipolar versus Unipolar Plus Bipolar Recordings During Segmental Ostial Ablation of Pulmonary Veins. Journal of Cardiovascular Electrophysiology, 2002, 13, 851-856.	1.7	24
119	Characteristics of Rapid Rhythms Recorded Within Pulmonary Veins During Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 1342-1347.	1.2	24
120	Initial Experience Using a Radiofrequency Powered Transseptal Needle. Journal of Cardiovascular Electrophysiology, 2010, 21, 423-427.	1.7	24
121	Patient characteristics as predictors of recurrence of atrial fibrillation following cryoballoon ablation. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 694-704.	1.2	24
122	Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2016, 27, 953-960.	1.7	23
123	Clinical Value of the Postpacing Interval for Mapping of Ventricular Tachycardia in Patients with Prior Myocardial Infarction. Journal of Cardiovascular Electrophysiology, 1999, 10, 43-51.	1.7	22
124	Mechanism of Immediate Recurrences of Atrial Fibrillation After Restoration of Sinus Rhythm. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 77-82.	1.2	22
125	ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy. Arrhythmia and Electrophysiology Review, 2016, 5, 188.	2.4	22
126	Moderate Sedation Reduces Lab Time Compared to General Anesthesia during Cryoballoon Ablation for AF Without Compromising Safety or Longâ€Term Efficacy. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 1359-1365.	1.2	22

#	Article	IF	CITATIONS
127	Discrete Systolic Potentials During Ventricular Tachycardia in Patients with Prior Myocardial Infarction. Journal of Cardiovascular Electrophysiology, 1999, 10, 364-369.	1.7	21
128	Attenuation of Oxidative Injury With Targeted Expression of NADPH Oxidase 2 Short Hairpin RNA Prevents Onset and Maintenance of Electrical Remodeling in the Canine Atrium. Circulation, 2020, 142, 1261-1278.	1.6	21
129	Relationship Between Shock Energy and Postdefibrillation Ventricular Arrhythmias in Patients with Implantable Defibrillators. Journal of Cardiovascular Electrophysiology, 1999, 10, 370-377.	1.7	20
130	Failure of Single- and Multisite High-Frequency Atrial Pacing to Terminate Atrial Fibrillation. American Journal of Cardiology, 1997, 80, 226-227.	1.6	19
131	Effects of Diltiazem and Esmolol on Cycle Length and Spontaneous Conversion of Atrial Fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics, 2002, 7, 81-88.	2.0	19
132	Integration of cardiac imaging and electrophysiology during catheter ablation procedures for atrial fibrillation. Journal of Electrocardiology, 2006, 39, \$188-\$192.	0.9	19
133	Long term risk of Wolff-Parkinson-White pattern and syndrome. Trends in Cardiovascular Medicine, 2017, 27, 260-268.	4.9	19
134	Effects of Verapamil and Ibutilide on Atrial Fibrillation and Postfibrillation Atrial Refractoriness. Journal of Cardiovascular Electrophysiology, 2002, 13, 151-157.	1.7	18
135	Permanent His bundle pacing at the time of atrioventricular node ablation: A 3-dimensional mapping approach. HeartRhythm Case Reports, 2017, 3, 323-325.	0.4	18
136	Region-specific parasympathetic nerve remodeling in the left atrium contributes to creation of a vulnerable substrate for atrial fibrillation. JCI Insight, 2019, 4, .	5.0	18
137	Emergency extracorporeal membrane oxygenation (ECMO)-supported percutaneous coronary interventions in the fibrillating heart. Catheterization and Cardiovascular Interventions, 1999, 48, 402-405.	1.7	17
138	Comparison of Verapamil and Ibutilide for the Suppression of Immediate Recurrences of Atrial Fibrillation after Transthoracic Cardioversion. Journal of Cardiovascular Pharmacology and Therapeutics, 2002, 7, 155-160.	2.0	17
139	Anticoagulation for Atrial Fibrillation Ablation. Journal of the American College of Cardiology, 2012, 59, 1175-1177.	2.8	17
140	The extravascular implantable cardioverterâ€defibrillator: The pivotal study plan. Journal of Cardiovascular Electrophysiology, 2021, 32, 2371-2378.	1.7	17
141	Update in Cardiac Pacing. Arrhythmia and Electrophysiology Review, 2019, 8, 228-233.	2.4	17
142	Comparison of Endocardial Activation Times at Effective and Ineffective Ablation Sites Within the Pulmonary Veins. Journal of Cardiovascular Electrophysiology, 2000, 11, 155-159.	1.7	16
143	Direct imaging of transvenous radiofrequency cardiac ablation using a steerable fiberoptic infrared endoscope. Heart Rhythm, 2005, 2, 1116-1121.	0.7	16
144	Ice formation in the left mainstem bronchus during cryoballoon ablation for the treatment of atrial fibrillation. Heart Rhythm, 2016, 13, 814-815.	0.7	16

#	Article	IF	CITATIONS
145	Gender differences in outcomes after surgical ablation of atrial fibrillation. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 391-398.e2.	0.8	16
146	Randomized Comparison of Two Techniques for Titrating Power During Radiofrequency Ablation of Accessory Pathways. Journal of Cardiovascular Electrophysiology, 1996, 7, 795-801.	1.7	15
147	Differential Effect of Adenosine on Anterograde and Retrograde Fast Pathway Conduction in Patients with Atrioventricular Nodal Reentrant Tachycardia. Journal of Cardiovascular Electrophysiology, 1998, 9, 820-824.	1.7	15
148	Effects of Isoproterenol and Amiodarone on the Double Potential Interval After Ablation of the Cavotricuspid Isthmus. Journal of Cardiovascular Electrophysiology, 2003, 14, 935-939.	1.7	15
149	Prophylactic pacemaker use to allow \hat{l}^2 -blocker therapy in patients with chronic heart failure with bradycardia. American Heart Journal, 2006, 151, 820-828.	2.7	15
150	Reversible, Complete Atrioventricular Block Caused by Primary Cardiac Lymphoma in a Nonimmunocompromised Patient. Journal of Cardiovascular Electrophysiology, 2012, 23, 1386-1389.	1.7	15
151	Medical Misinformation: Vet the Message!. Journal of the American Heart Association, 2019, 8, e011838.	3.7	15
152	Robotic positioning of standard electrophysiology catheters: a novel approach to catheter robotics. Journal of Invasive Cardiology, 2008, 20, 250-3.	0.4	15
153	Paroxysmal Fibrillation Within an Isolated Pulmonary Vein. Circulation, 2002, 106, 1426-1427.	1.6	14
154	Approaches to catheter ablation of persistent atrial fibrillation. Heart Rhythm, 2009, 6, S33-S38.	0.7	14
155	Left Atrial Thrombus Formation After Successful Left Atrial Appendage Ligation. Journal of the American College of Cardiology, 2015, 65, 1595-1596.	2.8	14
156	Sex Differences in Ablation Strategy, Lesion Sets, and Complications of Catheter Ablation for Atrial Fibrillation: An Analysis From the GWTG-AFIB Registry. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009790.	4.8	14
157	Analysis of age of onset of accessory pathway-mediated tachycardia in men and women. American Journal of Cardiology, 2002, 89, 470-471.	1.6	13
158	Atrial Fibrillation in Patients with Congestive Heart Failure. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 1620-1623.	1.2	13
159	HRS Policy Statement: Clinical Cardiac Electrophysiology Fellowship Curriculum: Update 2011. Heart Rhythm, 2011, 8, 1340-1356.	0.7	13
160	Optimal Strategies Including Use of Newer Anticoagulants for Prevention of Stroke and Bleeding Complications Before, During, and After Catheter Ablation of Atrial Fibrillation and Atrial Flutter. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 450-466.	0.9	13
161	Pacemakers in MRI for the Neuroradiologist. American Journal of Neuroradiology, 2017, 38, 2222-2230.	2.4	13
162	Multicenter Experience of Concomitant Use ofÂLeft Ventricular Assist Devices and Subcutaneous Implantable Cardioverter-Defibrillators. JACC: Clinical Electrophysiology, 2018, 4, 1261-1262.	3.2	13

#	Article	IF	Citations
163	A novel risk model for very late return of atrial fibrillation beyond 1Âyear after cryoballoon ablation: the SCALE-CryoAF score. Journal of Interventional Cardiac Electrophysiology, 2020, 58, 209-217.	1.3	13
164	Effect of electrode polarity on the energy required for transthoracic atrial defibrillation. American Journal of Cardiology, 1999, 84, 228-230.	1.6	12
165	Relationship Between Serum Potassium Concentration and Risk of Recurrent Ventricular Tachycardia or Ventricular Fibrillation. Journal of Cardiovascular Electrophysiology, 2001, 12, 1109-1112.	1.7	12
166	Tachycardia and Bradycardia Coexisting in the Same Pulmonary Vein. Journal of Cardiovascular Electrophysiology, 2002, 13, 186-188.	1.7	12
167	Medtronic Sprint Fidelis lead recall: Determining the initial 5-year management cost to Medicare. Heart Rhythm, 2011, 8, 1192-1197.	0.7	12
168	Comparison of atrial—his intervals in patients with and without dual atrioventricular nodal physiology and atrioventricular nodal reentrant tachycardia. American Heart Journal, 1996, 132, 758-764.	2.7	11
169	Postmortem Analysis and Retrieval of Implantable Pacemakers and Defibrillators. New England Journal of Medicine, 2006, 354, 1649-1650.	27.0	11
170	Assessing patients for catheter ablation during hospitalization for acute heart failure. Heart Failure Reviews, 2011, 16, 467-476.	3.9	11
171	Incidence and Clinical Significance of Inducible Atrial Tachycardia in Patients with Atrioventricular Nodal Reentrant Tachycardia. Journal of Cardiovascular Electrophysiology, 2001, 12, 507-510.	1.7	10
172	Supraventricular Tachycardia with Alternating Cycle Length: What is the Mechanism?. Journal of Cardiovascular Electrophysiology, 2001, 12, 1329-1330.	1.7	10
173	Effect of diltiazem on the recurrence rate of paroxysmal atrial fibrillation. American Journal of Cardiology, 2001, 88, 568-570.	1.6	10
174	Human Pathologic Validation of Left Ventricular Linear Lesion Formation Guided by Noncontact Mapping. Journal of Cardiovascular Electrophysiology, 2002, 13, 79-82.	1.7	10
175	Sustained quality-of-life improvement post-cryoballoon ablation in patients with paroxysmal atrial fibrillation: Results from the STOP-AF Post-Approval Study. Heart Rhythm, 2020, 17, 485-491.	0.7	10
176	Patientâ€reported outcomes after cryoballoon ablation are equivalent between moderate sedation and general anesthesia. Journal of Cardiovascular Electrophysiology, 2020, 31, 1579-1584.	1.7	10
177	Impact of preâ€ablation weight loss on the success of catheter ablation for atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2021, 32, 2097-2104.	1.7	10
178	Device-related infection in de novo transvenous implantable cardioverter-defibrillator Medicare patients. Heart Rhythm, 2021, 18, 1301-1309.	0.7	10
179	Use of a novel 4D intracardiac echocardiography catheter to guide interventional electrophysiology procedures. Journal of Cardiovascular Electrophysiology, 2021, 32, 3117-3124.	1.7	10
180	Comparing the safety and effectiveness of dedicated radiofrequency transseptal wires to electrified metal guidewires. Journal of Cardiovascular Electrophysiology, 2022, 33, 371-379.	1.7	10

#	Article	IF	CITATIONS
181	Transseptal access: A review of contemporary tools. Journal of Cardiovascular Electrophysiology, 2022, 33, 1927-1931.	1.7	10
182	Predictors of Crossover to a Left Ventricular Approach for Atrioventricular Junction Ablation. American Journal of Cardiology, 1997, 80, 1611-1612.	1.6	9
183	Cardiac electrophysiologic effects of norepinephrine in human beings. American Heart Journal, 1998, 135, 945-951.	2.7	9
184	The Totally Subcutaneous Implantable Defibrillator. Cardiology Clinics, 2014, 32, 225-237.	2.2	9
185	Repeat pulmonary vein isolation with or without FIRMâ€guided ablation for recurrent atrial fibrillation with pulmonary vein reconnection. Journal of Cardiovascular Electrophysiology, 2020, 31, 1031-1037.	1.7	9
186	Radiographic Appearance of Biventricular Pacing for the Treatment of Heart Failure. American Journal of Roentgenology, 2001, 177, 1447-1450.	2.2	8
187	Diagnosis and management of subcutaneous implantable cardioverterâ€defibrillator infections based on process mapping. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 958-965.	1.2	8
188	Effect of atrial fibrillation duration on probability of immediate recurrence after transthoracic cardioversion. Journal of Cardiovascular Electrophysiology, 2003, 14, 182-5.	1.7	8
189	The development of the extravascular defibrillator with substernal lead placement: A new Frontier for deviceâ€based treatment of sudden cardiac arrest. Journal of Cardiovascular Electrophysiology, 2022, 33, 1085-1095.	1.7	8
190	CATHETER ABLATION OF ACCESSORY PATHWAYS. Cardiology Clinics, 1997, 15, 647-660.	2.2	7
191	Effect of isoproterenol on QRS complex morphology during ventricular pacing: Implications for pace mapping. Journal of Electrocardiology, 1998, 31, 133-136.	0.9	7
192	Comparison of amiodarone versus ibutilide for the prevention of immediate recurrences of atrial fibrillation during pulmonary vein isolation. American Journal of Cardiology, 2002, 90, 492-495.	1.6	7
193	Alcohol ablation for ventricular tachycardia: A distillation of modern cases. Heart Rhythm, 2008, 5, 69-70.	0.7	7
194	Double transseptal catheterization guided by real-time 3-dimensional transesophageal echocardiography. Heart Rhythm, 2008, 5, 324-325.	0.7	7
195	Transesophageal Echocardiography Before Atrial Fibrillation Ablation. Journal of the American College of Cardiology, 2009, 54, 2040-2042.	2.8	7
196	Latency of ECG Displays of Hospital Telemetry Systems. Circulation, 2012, 126, 1665-1669.	1.6	7
197	Left Atrial Appendage Closure. Progress in Cardiovascular Diseases, 2015, 58, 195-201.	3.1	7
198	Left ventricular pseudoaneurysm as a complication of left ventricular summit premature ventricular contraction ablation. HeartRhythm Case Reports, 2017, 3, 268-271.	0.4	7

#	Article	IF	CITATIONS
199	Outcomes Associated With Electrical Cardioversion for Atrial Fibrillation WhenÂPerformed Autonomously by anÂAdvanced Practice Provider. JACC: Clinical Electrophysiology, 2017, 3, 1447-1452.	3.2	7
200	Avoiding damage to transvenous leads-A comparison of electrocautery techniques and two insulated electrocautery blades. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1593-1599.	1.2	7
201	Wideband LGE MRI permits unobstructed viewing of myocardial scarring in a patient with an MR-conditional subcutaneous implantable cardioverter-defibrillator. Clinical Imaging, 2018, 50, 294-296.	1.5	7
202	Increased risk of hematoma with uninterrupted warfarin in patients undergoing implantation of subcutaneous implantable cardioverter defibrillator. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1111-1114.	1,2	7
203	Wideband myocardial perfusion pulse sequence for imaging patients with a cardiac implantable electronic device. Magnetic Resonance in Medicine, 2019, 81, 1219-1228.	3.0	7
204	Management of systemic fungal infections in the presence of a cardiac implantable electronic device: A systematic review. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 159-166.	1.2	7
205	Outcomes With Novel Oral Anticoagulants in Obese Patients who Underwent Electrical Cardioversion for Atrial Tachyarrhythmias. American Journal of Cardiology, 2018, 122, 1175-1178.	1.6	6
206	Ablation of Supraventricular Tachycardias From Concealed Left-Sided Nodoventricular and Nodofascicular Accessory Pathways. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007853.	4.8	6
207	Procedure characteristics and outcomes of atrial fibrillation ablation procedures using cryoballoon versus radiofrequency ablation: A report from the GWTGâ€AFIB registry. Journal of Cardiovascular Electrophysiology, 2021, 32, 248-259.	1.7	6
208	Target Temperatures of 48°C versus 60°C During Slow Pathway Ablation:. Journal of Cardiovascular Electrophysiology, 1999, 10, 799-803.	1.7	5
209	Inappropriate activation of pacemaker magnet response mode by CPAP masks. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1158-1161.	1.2	5
210	Evolution of extravascular implantable defibrillator technologies. Progress in Cardiovascular Diseases, 2019, 62, 249-255.	3.1	5
211	Competitive bidding for interventional cardiology supplies: lessons learned during round 2. American Journal of Managed Care, 2002, 8, 384-8.	1.1	5
212	Hybrid Convergent ablation for atrial fibrillation: A systematic review and meta-analysis. Heart Rhythm O2, 2022, 3, 396-404.	1.7	5
213	Optimal Management of the Patient with an Episode of Atrial Fibrillation In and Out of the Hospital Journal of Cardiovascular Electrophysiology, 1999, 10, 425-432.	1.7	4
214	Augmentation of Pulsus Alternans by a PrematureVentricular Beat. Journal of Cardiovascular Electrophysiology, 2006, 17, 918-918.	1.7	4
215	Catheter ablation for ventricular tachycardia: indications and techniques. Expert Review of Cardiovascular Therapy, 2007, 5, 977-988.	1.5	4
216	Electrical and Pharmacologic Cardioversion for Atrial Fibrillation. Medical Clinics of North America, 2008, 92, 101-120.	2.5	4

#	Article	IF	Citations
217	Guidance for the Heart Rhythm Society Pertaining to Interactions with Industry. Heart Rhythm, 2011, 8, e19-e25.	0.7	4
218	The subcutaneous implantable cardioverter and defibrillator: advantages, limitations and future directions. Expert Review of Cardiovascular Therapy, 2015, 13, 989-999.	1.5	4
219	Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias. Arrhythmia and Electrophysiology Review, 2016, 5, 210.	2.4	4
220	Increased capture threshold in permanent Hisâ€bundle pacing associated with flecainide. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 360-363.	1.2	4
221	Association of the H ₂ FPEF Risk Score with Recurrence of Atrial Fibrillation Following Pulmonary Vein Isolation. Journal of Atrial Fibrillation, 2020, 12, 2295.	0.5	4
222	Effect of ethanol on defibrillation energy requirements in humans. American Journal of Cardiology, 2000, 85, 117-119.	1.6	3
223	Effect of atrial fibrillation on chamber dimensions. Heart Rhythm, 2005, 2, 25-27.	0.7	3
224	Widely-Split Double Potentials at the Pulmonary Vein Ostium in Patients with Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1412-1415.	1.2	3
225	Marker Annotation Misalignment on a Defibrillator Interrogation Printout. Journal of Cardiovascular Electrophysiology, 2007, 18, 1216-1217.	1.7	3
226	Epicardial atrial fat: Not quite as idle as it looks. Heart Rhythm, 2015, 12, 266-267.	0.7	3
227	What happens during the blanking period does not stay in the blanking period. Journal of Cardiovascular Electrophysiology, 2017, 28, 634-635.	1.7	3
228	Permanent Hisâ€Bundle pacing in a patient with advanced conduction system disease: What is the mechanism of <scp>QRS</scp> narrowing?. Clinical Case Reports (discontinued), 2018, 6, 1236-1240.	0.5	3
229	Characterization of atrial flutter after pulmonary vein isolation by cryoballoon ablation. Journal of Interventional Cardiac Electrophysiology, 2020, 57, 233-240.	1.3	3
230	From 100 to 0. JACC: Case Reports, 2020, 2, 1173-1177.	0.6	3
231	Improvement in renal function following cryoballoon ablation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2021, 60, 513-520.	1.3	3
232	Evaluation of image quality of wideband singleâ€shot late gadoliniumâ€enhancement MRI in patients with a cardiac implantable electronic device. Journal of Cardiovascular Electrophysiology, 2021, 32, 138-147.	1.7	3
233	Physiologic lead placement with electroanatomic mapping: A case series. Journal of Cardiovascular Electrophysiology, 2021, 32, 3195-3202.	1.7	3
234	Catheter ablation for atrial fibrillation. Indian Pacing and Electrophysiology Journal, 2003, 3, 210-23.	0.6	3

#	Article	IF	Citations
235	Cost Analysis of Transthoracic Cardioversion of Atrial Fibrillation With and Without Ibutilide Pretreatment. Journal of Cardiovascular Pharmacology and Therapeutics, 2000, 5, 259-266.	2.0	2
236	Unusual Response to Ventricular Pacing During a Long RP Tachycardia. Journal of Cardiovascular Electrophysiology, 2004, 15, 241-243.	1.7	2
237	Repeat Ablation for Atrial Fibrillation:. Just a Second Go-Around?. Journal of Cardiovascular Electrophysiology, 2004, 15, 1056-1057.	1.7	2
238	Termination of Epicardial Left Ventricular Tachycardia by Pacing without Global Capture. Journal of Cardiovascular Electrophysiology, 2005, 16, 92-94.	1.7	2
239	Imaging techniques in cardiac electrophysiology. Expert Review of Cardiovascular Therapy, 2006, 4, 59-70.	1.5	2
240	Defibrillator Therapies in Hypertrophic Cardiomyopathy: Too Many Swings at Bad Pitches?. Journal of Cardiovascular Electrophysiology, 2007, 18, 488-489.	1.7	2
241	Pseudo Pacemaker Stimuli. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 513-516.	1.2	2
242	Ablate and Pace. Cardiac Electrophysiology Clinics, 2012, 4, 403-412.	1.7	2
243	Chest Pain and T-Wave Inversions in a 56-Year-Old Man. Circulation, 2017, 135, 998-1000.	1.6	2
244	Management of Sâ€ICD lead in a patient requiring sternotomy. Clinical Case Reports (discontinued), 2019, 7, 1309-1311.	0.5	2
245	Value of high-density mapping in the electrophysiology laboratory. Current Opinion in Cardiology, 2019, 34, 6-15.	1.8	2
246	Left ventricular extracellular volume expansion does not predict recurrence of atrial fibrillation following catheter ablation. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 159-166.	1.2	2
247	Left Ventricular Extracellular Volume Expansion Is Not Associated with Atrial Fibrillation or Atrial Fibrillation–mediated Left Ventricular Systolic Dysfunction. Radiology: Cardiothoracic Imaging, 2020, 2, e190096.	2.5	2
248	The problematic lag between FDA approval of medical devices and CMS coverage. Journal of Cardiovascular Electrophysiology, 2021, 32, 1801-1802.	1.7	2
249	Deviceâ€related infection associated with increased mortality risk in de novo transvenous implantable cardioverterâ€defibrillator medicare patients. Journal of Cardiovascular Electrophysiology, 2022, , .	1.7	2
250	Process Mapping Strategies to Prevent Subcutaneous Implantable Cardioverterâ€Defibrillator Infections. Journal of Cardiovascular Electrophysiology, 0, , .	1.7	2
251	Supraventricular tachyarrhythmia. Current Treatment Options in Cardiovascular Medicine, 2000, 2, 297-308.	0.9	1
252	Pulmonary Vein Ablation:. Looking While Cooking. Journal of Cardiovascular Electrophysiology, 2004, 15, 168-169.	1.7	1

#	Article	IF	CITATIONS
253	Pace termination of left atrial flutter after ablation for atrial fibrillation: What is the mechanism?. Heart Rhythm, 2008, 5, 1619-1620.	0.7	1
254	Shoulder arthroscopy in patients with a cardiac pacemaker or defibrillator: A case report and discussion of perioperative management. Journal of Shoulder and Elbow Surgery, 2010, 19, 1204-1209.	2.6	1
255	A Pilot Study Evaluating Daily Physical Activity Before and After Cardiac Resynchronization Therapy. Biological Research for Nursing, 2014, 16, 31-37.	1.9	1
256	The flu and atrial fibrillation: Nothing to sneeze at. Heart Rhythm, 2016, 13, 1195-1196.	0.7	1
257	New Heart…New Rhythm. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 67-68.	1.2	1
258	What Is the Role of Left Atrial Appendage Closure in the Rhythm Control of Atrial Fibrillation?. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 24.	0.9	1
259	Fusion during entrainment at the cavotricuspid isthmus: What is the mechanism?. Heart Rhythm, 2018, 15, 787-789.	0.7	1
260	Reply:. American Journal of Neuroradiology, 2018, 39, E37-E37.	2.4	1
261	Left atrial appendage isolation at the time of atrial fibrillation ablation. Heart Rhythm, 2018, 15, 1754-1755.	0.7	1
262	New DEStiny Revealed. Circulation, 2018, 138, 1267-1271.	1.6	1
263	Inappropriate defibrillator shock during gynecologic electrosurgery. HeartRhythm Case Reports, 2018, 4, 267-269.	0.4	1
264	Use of the cryoballoon to ablate pulmonary veinâ€dependent left atrial flutter. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1589-1593.	1.2	1
265	Conduction Abnormalities and Ischemic Cardiomyopathy in an 84-Year-Old Man. Circulation, 2020, 141, 1268-1270.	1.6	1
266	B-PO04-064 A PROSPECTIVE EVALUATION OF SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR INFECTIONS WITH MID TERM FOLLOW-UP. Heart Rhythm, 2021, 18, S304-S305.	0.7	1
267	Evaluation of a Novel Cardiac Signal Processing System for Electrophysiology Procedures: The PURE EP 2.0 Study. Journal of Cardiovascular Electrophysiology, 2021, 32, 2915-2922.	1.7	1
268	Reconnection Rate and Long-Term Outcome with Adenosine Provocation During Cryoballoon Ablation for Pulmonary Vein Isolation. Journal of Atrial Fibrillation, 2017, 9, 1510.	0.5	1
269	Case report: DSP truncation variant p. R1951X leads to arrhythmogenic left ventricular cardiomyopathy. European Heart Journal - Case Reports, 2022, 6, ytac105.	0.6	1
270	Influence of right ventricular site of stimulation and infarct location on the inducibility of ventricular tachycardia in patients with coronary artery disease. Journal of Electrocardiology, 1998, 31, 278-280.	0.9	0

#	Article	IF	CITATIONS
271	A Narrow QRS Complex Tachycardia: Journal of Cardiovascular Electrophysiology, 1999, 10, 1429-1431.	1.7	O
272	Biventricular pacing for dilated cardiomyopathy: proper patient selection. ACC Current Journal Review, 2002, 11, 77-80.	0.1	0
273	Recurrent Syncope in a Patient with an Implantable Loop Recorder: What is the Diagnosis?. Journal of Cardiovascular Electrophysiology, 2002, 13, 1176-1177.	1.7	0
274	Three supraventricular tachycardias: How can all three occur in the same patient?. Heart Rhythm, 2005, 2, 890-892.	0.7	0
275	A novel transparent electrode that permits direct imaging during radiofrequency catheter ablation. Heart Rhythm, 2005, 2, S73.	0.7	0
276	AB30-2. Heart Rhythm, 2006, 3, S62.	0.7	0
277	The management of implantable cardiac devices at the end of life. Progress in Palliative Care, 2008, 16, 250-256.	1.2	0
278	Integrated Imaging of Atrial Fibrillation in 2010. Current Cardiovascular Imaging Reports, 2010, 3, 286-293.	0.6	0
279	Using Floating Atrial Electrodes to Combat the Rising Tide of Inappropriate Defibrillator Therapies. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 5-7.	4.8	0
280	Drug challenge with sodium-channel blockade: Improving phenotypic characterization of early repolarization. Heart Rhythm, 2012, 9, 240-241.	0.7	0
281	An Unusual Level of Block in a Patient With an Unusual Accessory Pathway. Journal of Cardiovascular Electrophysiology, 2012, 23, 334-335.	1.7	0
282	The Potential Role of Nonpharmacologic Electrophysiology-Based Interventions in Improving Outcomes in Patients Hospitalized for Heart Failure. Heart Failure Clinics, 2013, 9, 331-343.	2.1	0
283	SAFE Combinations Fail to Open the Door to Atrial Fibrillation Prevention. Circulation, 2013, 128, 679-680.	1.6	0
284	Ablation OFF?. Journal of Cardiovascular Electrophysiology, 2013, 24, 720-722.	1.7	0
285	PVCâ€Induced Second Tachycardia. Journal of Cardiovascular Electrophysiology, 2015, 26, 694-695.	1.7	0
286	Ablation for Persistent Atrial Fibrillation. JACC: Clinical Electrophysiology, 2015, 1, 161-163.	3.2	0
287	Atrial flutter and thromboembolic risk. Heart, 2015, 101, 1444-1445.	2.9	0
288	Manifest Left Atrial Appendage Delay on a 12‣ead EKG After AF Ablation. Journal of Cardiovascular Electrophysiology, 2016, 27, 492-493.	1.7	0

#	Article	IF	CITATIONS
289	Ventricular Overdrive Pacing: Beyond Vâ€Aâ€V and Vâ€Aâ€Aâ€V. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 113-114.	1.2	O
290	Inadvertent Side Exit of Transseptal Needle Stylet. Journal of Cardiovascular Electrophysiology, 2017, 28, 573-573.	1.7	0
291	Response by Verma and Knight to Letter Regarding Article, "Chest Pain and T-Wave Inversions in a 56-Year-Old Man― Circulation, 2017, 136, 784-784.	1.6	0
292	Editorial Commentary: Indications for catheter ablation of ventricular tachycardia in the modern era. Trends in Cardiovascular Medicine, 2017, 27, 514-515.	4.9	0
293	Reply to the Editor— Fusion during entrainment at the cavotricuspid isthmus: When entrainment does not match our expectation. Heart Rhythm, 2018, 15, e275.	0.7	0
294	INAPPROPRIATE ACTIVATION OF PACEMAKER MAGNET MODE BY A CPAP MASK. Journal of the American College of Cardiology, 2019, 73, 497.	2.8	0
295	Premature atrial complexes and atrial couplets: What is the mechanism?. Journal of Cardiovascular Electrophysiology, 2020, 31, 3339-3342.	1.7	0
296	Difficult posteroseptal pathway ablation and recurrent PSVT. Journal of Cardiovascular Electrophysiology, 2020, 31, 985-987.	1.7	0
297	Content published in JCE during 2020. Journal of Cardiovascular Electrophysiology, 2021, 32, 7-8.	1.7	0
298	B-PO02-029 REDUCED ATRIAL FIBRILLATION DRIVERS IN RESPONSE TO REACTIVE OXYGEN SCAVENGING - A NOVEL THERAPEUTIC TARGET IN ATRIAL FIBRILLATION?. Heart Rhythm, 2021, 18, S106.	0.7	0
299	Cover Image, Volume 32, Issue 9. Journal of Cardiovascular Electrophysiology, 2021, 32, i.	1.7	0
300	Delayed occurrence of atypical fast-slow atrioventricular nodal reentry years after successful slow pathway ablation for typical atrioventricular nodal reentry. HeartRhythm Case Reports, 2020, 6, 960-962.	0.4	0
301	Cover Image, Volume 32, Issue 11. Journal of Cardiovascular Electrophysiology, 2021, 32, i.	1.7	0
302	A shocking cause of nighttime arrhythmias. Journal of Cardiovascular Electrophysiology, 2022, 33, 756-760.	1.7	0
303	Corticosteroids prevented atrial fibrillation after cardiac surgery. ACP Journal Club, 2007, 147, 36.	0.1	0
304	BS-400-37 TARGETED ATRIAL EXPRESSION OF NGF SHRNA ATTENUATES NEW PARASYMPATHETIC AND SYMPATHETIC NERVE SPROUTING AND RESULTING DEVELOPMENT OF PERSISTENT ATRIAL FIBRILLATION IN A CANINE MODEL - A NOVEL GENE THERAPY APPROACH TO ATRIAL FIBRILLATION. Heart Rhythm, 2022, 19, S509.	0.7	0
305	PO-691-06 UNCOVERING REGIONS OF HIGH OXIDATIVE INJURY IN PERSISTENT ATRIAL FIBRILLATION PATIENTS AND IN A CANINE MODEL WITH ACUTE ADMINISTRATION OF N-ACYTYLCYSTEINE — A NEW THERAPEUTIC TARGET IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION?. Heart Rhythm, 2022, 19, S400-S401.	0.7	0
306	BS-512-04 TARGETED ATRIAL EXPRESSION OF NGF SHRNA ATTENUATES NEW PARASYMPATHETIC AND SYMPATHETIC NERVE SPROUTING AND RESULTING DEVELOPMENT OF PERSISTENT ATRIAL FIBRILLATION IN A CANINE MODEL - A NOVEL GENE THERAPY APPROACH TO ATRIAL FIBRILLATION. Heart Rhythm, 2022, 19, S6-S7.	0.7	0

#	Article	IF	CITATIONS
307	Best of the HRS 2009 Scientific Sessions. Reviews in Cardiovascular Medicine, 2009, 10, 168-170.	1.4	O